Article Information
vol. 6 no. 4
Published By
Online ISSN
History
- Received April 15, 2020
- Accepted August 28, 2020
- Published online November 10, 2020.
Article Versions
- previous version (October 8, 2020 - 09:42).
- You are viewing the most recent version of this article.
Copyright & Usage
Copyright ©ERS 2020 This article is open access and distributed under the terms of the Creative Commons Attribution Licence 4.0.
Author Information
- Marjan Kerkhof1,
- Isha Chaudhry1,
- Ian D. Pavord2,
- Marc Miravitlles3,
- Chin Kook Rhee4,
- David M.G. Halpin5,
- Omar S. Usmani6,
- Rupert Jones7,
- Janwillem Kocks1,
- Marianna Alacqua8,
- Tamsin Morris9,
- Alan Kaplan1,10 and
- David B. Price1,11⇑
- 1Observational and Pragmatic Research Institute, Singapore, Singapore
- 2Oxford Respiratory NIHR BRC, Nuffield Dept of Medicine, University of Oxford, Oxford, UK
- 3Pneumology Dept, Hospital Universitari Vall d'Hebron, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, CIBER de Enfermedades Respiratorias (CIBERES), Barcelona, Spain
- 4College of Medicine, Seoul St Mary's Hospital, The Catholic University of Korea, Seoul, South Korea
- 5University of Exeter Medical School, College of Medicine and Health, University of Exeter, Exeter, UK
- 6Imperial College London, London, UK
- 7The Peninsula College of Medicine and Dentistry, Plymouth, UK
- 8AstraZeneca, Cambridge, UK
- 9AstraZeneca, Luton, UK
- 10Family Physician Airways Group of Canada, Richmond Hill, ON, Canada
- 11University of Aberdeen, Aberdeen, UK
- David B. Price, Academic Primary Care, Division of Applied Health Sciences, University of Aberdeen, Polwarth Building, Foresterhill, Aberdeen, UK. E-mail: david{at}opri.sg
Funding
AstraZeneca
Article usage
Altmetrics
Vol 6 Issue 4
Table of Contents
Blood eosinophil count predicts treatment failure and hospital readmission for COPD
